Combination megestrol acetate, oxandrolone, and dietary advice restores weight in human immunodeficiency virus

Nutrition in Clinical Practice

Volumn 19, Issue 4, 2004, Pages 395-402

  Mwamburi, D Mkaya ^a   Gerrior, Jül ^b   Wilson, Ira B ^a   Chang, Hong ^a   Scully, Ed ^c   Saboori, Shiva ^c   Miller, Laurel ^d   Forfia, Janet ^d   Albrecht, Mary ^e   Wanke, Christine A ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Gtr Lawrence Mental Health Center   (United States)

^d Gtr New Bedford Comm Health Center   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEGESTROL ACETATE; OXANDROLONE;

ADULT; AGE; ARTICLE; BODY FAT; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DIETARY INTAKE; FEMALE; HEALTH; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LEAN BODY WEIGHT; LONGITUDINAL STUDY; MALE; MEDICAL DOCUMENTATION; MENTAL HEALTH; MULTIVARIATE ANALYSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEX DIFFERENCE; VIRUS LOAD; WASTING SYNDROME; WEIGHT GAIN;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 3242694124     PISSN: 08845336     EISSN: None     Source Type: Journal    
DOI: 10.1177/0115426504019004395     Document Type: Article

References (34)

1. Wanke CA, Silva M, Knox TA, Forrester J, Speigelman D, Gorbach SL. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;31:803-805.
2. Wheeler DA, Gibert CL, Launer CA, et al. Weight loss as a predictor of survival and disease progression in HIV infection: Terry Beirn Community Programs for Clinical Research on AIDS. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:80-85.
3. Palenicek JP, Graham NM, He YD, et al. Weight loss prior to clinical AIDS as a predictor of survival: Multicenter AIDS Cohort Study Investigators. J Acquir Immune Defic Syndr Hum Retrovirol. 1995; 10:366-373.
4. Melchior JC, Niyongabo T, Henzel D, Durack-Bown I, Henri SC, Boulier A. Malnutrition and wasting, immunodepression, and chronic inflammation as independent predictors of survival in HIV-infected patients. Nutrition. 1999;15:865-869.
5. Wilson IB, Jacobson DL, Roubenoff R, Spiegelman D, Knox TA, Gorbach SL. Changes in lean body mass and total body weight are weakly associated with physical functioning in patients with HIV infection. HIV Med. 2002;3:263-270.
6. Wilson IB, Roubenoff R, Knox TA, Spiegelman D, Gorbach SL. Relation of lean body mass to health-related quality of life in persons with HIV. J Acquir Immune Defic Syndr. 2000;24:137-146.
7. Perez De Oteyza C, Garcia Cortes A, Menendez Martinez MA, Torres Leon JM, Perez Aznar C, Carnicero Bujarrabal M. Megestrol in the treatment of AIDS associated cachexia: evaluation by bioelectric impedance analysis of body composition. Ann Med Int. 1998;15:255-258.
8. Summerbell CD, Youle M, McDonald V, Catalan J, Gazzard BG. Megestrol acetate vs cyproheptadine in the treatment of weight loss associated with HIV infection. Int J STD AIDS. 1992;3:278-280.
9. Von Roenn JH, Armstrong D, Kotler DP, et al. Megestrol acetate in patients with AIDS-related cachexia. Ann, Intern Med. 1994; 121:393-399.
10. Von Roenn JH, Murphy RL, Wegener N. Megestrol acetate for treatment of anorexia and cachexia associated with human immunodeficiency virus infection. Sem Oncol. 1990;17(6 Suppl 9):13-16.
11. Clarick RH, Hanekom WA, Yogev R, Chadwick EG. Megestrol acetate treatment of growth failure in children infected with human immunodeficiency virus. Pediatrics. 1997;99:354-357.
12. Earthman CP, Reid PM, Harper IT, Ravussin E, Howell WH. Body cell mass repletion and improved quality of life in HIV-infected individuals receiving oxandrolone. JPEN. 2002;26:357-365.
13. Fischer A. The Effects of Oxandrolone on Body Weight and Composition in Patients with HIV-Related Weight Loss. Geneva, Switzerland: 12th World AIDS Conference; 1998.
14. Berger JR, Pall L, Hall CD, Simpson DM, Berry PS, Dudley R. Oxandrolone in AIDS-wasting myopathy. AIDS. 1996;10:1657-1662.
15. Hellerstein M, Strawford A. Resistance exercise and oxandrolone for men with HIV-related weight loss. JAMA. 2000;284:176-177.
16. Taiwo BO. HIV-associated wasting: brief review and discussion of the impact of oxandrolone. AIDS Patient Care STD. 2000;14:421-425.
17. Nemechek PM, Polsky B, Gottlieb MS. Treatment guidelines for HIV-associated wasting. Mayo Clin Proc. 2000;75:386-394.
18. Grinspoon S, Corcoran C, Parlman K, et al. Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting: a randomized, controlled trial. Ann Intern Med. 2000; 133:348-355.
19. Strawford A, Barbieri T, Van Loan M, et al. Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss: a randomized controlled trial. JAMA. 1999;281:1282-1290.
20. Mwamburi DM, Gerrior J, Wilson IB, et al. Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: Similar results in 2 months. Clin Infect Dis. 2004;38:895-902.
21. Durnin JV, Womersley J. Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years. Br J Nutr. 1974;32:77-97.
22. Lukaski H. Use of bioelectric impedance analysis to assess human body composition: a review. In: Livingstone GE, ed. Nutritional Assessment of an Individual. Trumbull, CT: Food and Nutrition Press; 1989:189-204.
23. Ware J Jr, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220-233.
24. Farrar DJ. Megestrol acetate: promises and pitfalls. AIDS Patient Care STD. 1999; 13:149-152.
25. Engelson ES, Pi-Sunyer FX, Kotler DP. Effects of megestrol acetate therapy on body composition and circulating testosterone concentrations in patients with AIDS. AIDS. 1995;9:1107-1108.
26. Von Roenn JH, Murphy RL, Weber KM, Williams LM, Weitzman SA. Megestrol acetate for treatment of cachexia associated with human immunodeficiency virus (HIV) infection. Ann Intern Med. 1988;109:840-841.
27. Batterham MJ, Garsia R. A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss. Int J Androl. 2001;24:232-2340.
28. Lindsey JC, Hughes MD, McKinney RE, et al. Treatment-mediated changes in human immunodeficiency virus (HIV) type 1 RNA and CD4 cell counts as predictors of weight growth failure, cognitive decline, and survival in HIV-infected children. J Infect Dis. 2000;182:1385-1393.
29. Lyles RH, Tang AM, Smit E, et al. Virologic, immunologic, and immune activation markers as predictors of HIV-associated weight loss prior to AIDS: Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 1999;22:386-394.
30. Sorkin JD, Bolton PA, Greenblatt J, Sithisarankul P, Vlahov D, Graham NM. Age, gender, and other predictors of the wasting syndrome among HIV-1-infected injecting drug users. Epidemiology. 1995;6:172-177.
31. Mkaya Mwamburi DJ, Wilson IB, Wanke CA. The Relationship Between Changes in HIV Viral Load and Body Weight in Patients with HIV. Banff, Alberta, Canada: Keystone Symposium in HIV; 2003.
32. Corcoran C, Anderson EJ, Burrows B, et al. Comparison of total body potassium with other techniques for measuring lean body mass in men and women with AIDS wasting. Am J Clin Nutr. 2000;72:1053-1058.
33. Paton NI, Elia M, Jennings G, Ward LC, Griffin GE. Bioelectrical impedance analysis in human immunodeficiency virus-infected patients: comparison of single frequency with multifrequency, spectroscopy, and other novel approaches. Nutrition. 1998;14: 658-666.
34. Kotler DP, Burastero S, Wang J, Pierson RN Jr. Prediction of body cell mass, fat-free mass, and total body water with bioelectrical impedance analysis: effects of race, sex, and disease. Am J Clin Nutr. 1996;64(3 suppl):489S-497S.